LINDSEY FENZEL: Open Payments
NPI 1912283425 · LEES SUMMIT, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$364 in 15 payments from 7 companies in 2025. Trend: 2023 $0 · 2024 $257 · 2025 $364
Food & beverage: $364
| Company | Payments | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC | 3 | $109 |
| Novartis Pharmaceuticals Corporation | 5 | $103 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $52 |
| GENZYME CORPORATION | 2 | $37 |
| GlaxoSmithKline, LLC. | 1 | $24 |
| Incyte Corporation | 1 | $20 |
| Stemline Therapeutics Inc. | 1 | $19 |
Products named: KEYTRUDA, KISQALI, ALUNBRIG, SARCLISA, PLUVICTO, JEMPERLI, MONJUVI, Orserdu.
Industry payments across MO — which companies pay providers there.
